Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 20, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 675,000 ordinary shares of 25 pence each.
- Purchase Price: 1,473.1901 pence per share.
- Treasury Holdings: 144,129,678 shares held in Treasury following the transaction.
- Shares in Issue: 5,823,616,132 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback authorized by shareholders at the Annual General Meeting on May 25, 2005. The filing does not provide comparative data against prior periods for operational metrics.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total cost of the 675,000 shares purchased at 1,473.1901 pence per share.
- Confirm the updated total number of shares in issue (5,823,616,132) and Treasury holdings (144,129,678).
- Review the original shareholder authorization from the May 25, 2005 Annual General Meeting to ensure the repurchase was within approved limits.